Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 daratumumab monotherapy in previously untreated stage 3B AL amyloidosis
2018-004333-33Phase 2Completed
- Sponsor
- European Myeloma Network
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in light-chain amyloidosis, sponsored by European Myeloma Network. Primary endpoint: Overall survival rate. Started Jun 2019; status: completed.
02
Drugs
daratumumab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2018-004333-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004333-33.